Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis By admin / 10/23/2024
Comparison of Multiple Sclerosis Disease Activity (MSDA) Test Results Between Patients Treated with Ublituximab and Teriflunomide in the Phase 3 ULTIMATE I and II Studies By admin / 09/18/2024
Five Years of Ublituximab in Relapsing Multiple Sclerosis: Results from the Open-Label Extension of ULTIMATE I and II Studies By admin / 09/18/2024
Efficacy and Tolerability of Ublituximab after Transitioning from a Different Disease-Modifying Therapy: Updates from the ENHANCE Study By admin / 09/18/2024
BRIUMVI® Pregnancy Registry: A Prospective Study of Pregnancy and Infant Outcomes in Patients Treated with BRIUMVI (ublituximab-xiiy) By admin / 05/30/2024
A Post-Marketing Study Evaluating the Presence and Concentration of BRIUMVI®(ublituximab-xiiy) in Breastmilk (PROVIDE) By admin / 05/30/2024
Early Initiation of Ublituximab Treatment is Associated with Improved Disability Outcomes Among Treatment-Naïve Participants in ULTIMATE I and II By admin / 04/17/2024
Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies By admin / 04/17/2024
MS Relapse Redefined: Distinguishing True Relapses from Pseudoexacerbations in the ULTIMATE I and II Trials Comparing Ublituximab vs Teriflunomide By admin / 04/14/2024
Evaluating the Maintenance of Efficacy and Tolerability of Transitioning from IV Anti-CD20 Therapy to Ublituximab: ENHANCE Study Interim Data By admin / 02/29/2024
